The Virtual CVOT Summit 2023 will start on 30 November at 15:00 CET.The livestream will start today at 15:00 CET.Welcome and Introduction15:00 – 15:10 CETSchnell O (Munich, Germany)Management of CKD in 2023: an update of guidelines15:10 – 15:25 Groop P-H (Helsinki, Finland)What`s new in the ESC “Diabetes and the Heart” and “Heart Failure” Guidelines 202315:25 – 15:40 Marx N (Aachen, Germany)Discussion15:40 – 15:50Treatment for Type 2 Diabetes: systematic review and network meta-analysis for the creation of living guidelines15:50 – 16:05 Rydén L (Stockholm, Sweden)Join the Alliance for Living Evidence (Alive)!16:05 – 16:20 Tendal Jeppesen B (Copenhagen, Denmark)Strengthening the recognition of minority groups in clinical guidelines for diabetes16:20 – 16:35Gavin JR (Atlanta, USA)Discussion16:35 – 16:50Break16:50 – 17:00 CETConsensus statement on PROs - why, how and what does it matter?17:00 – 17:15 Barnard-Kelly K (Hampshire, UK)IDF perspective on PROs17:15 – 17:30Schwarz P (Dresden, Germany)PROs: What are governments doing in this space and how do they influence policy?17:30 – 17:45Taylor B (Tampa, USA)Patient´s perspectives on PROs17:45 – 18:00Huntley G (Indianapolis, USA)Discussion18:00 – 18:30Break18:30 – 18:45 CETMultireceptor drugs for obesity: a new emerging universe18:45 – 19:05Müller T (Munich, Germany)Discussion19:05 – 19:15New horizons for CGM in diabetes: further building a key pillar of diabetes management19:15 – 19:35Battelino T (Ljubljana, Slovenia)Discussion19:35 – 19:45OP 1: Lipid-Lowering Treatments and Risk of Cardiovascular Events in Over 9000 Patients From 14 European Countries: 1-year Prospective Follow-Up of the SANTORINI RegistryAguiar C (Carnaxide, Portugal)OP 2: Benefit of Dual Therapy With GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 DiabetesKvist K (Søborg, Denmark)OP 3: Tirzepatide Reduces Albuminuria in Patients With Type 2 Diabetes: Post-Hoc Pooled Analysis of SURPASS 1-5Ranta K (Helsinki, Finland)OP 4: Impact of Finerenone on Chronic Kidney Disease Progression in Chinese Patients With Type 2 Diabetes: FIGARO-DKD Subgroup AnalysisBrinker M (Wuppertal, Germany)OP 5: A cross-sectional survey on CKD diagnosis and managementRötzer R (Munich, Germany)Closing of Day 120:45 CETThe Virtual CVOT Summit 2023 continues tomorrow, Friday December 01, at 08:30 CET. We look forward to your participation!The Virtual CVOT Summit 2023 continues tomorrow, Friday, 01 December, at 08:30 CET. We look forward to your participation!The livestream will start today at 08:30 CET.Type 1 Diabetes: early detection and preventive approaches08:30 – 08:45Larsson HE (Lund, Sweden)Teplizumab – Delaying the onset of Type 1 Diabetes08:45 – 09:00Mathieu C (Leuven, Belgium)Treatment strategies for neuropathy in Type 1 Diabetes09:00 – 09:15 Tesfaye S (Sheffield, UK)Preventing and delaying the progression of chronic kidney disease (CKD) in Type 1 Diabetes 09:15 – 09:30 Groop P-H (Helsinki, Finland)Discussion09:30 – 09:50Break09:50 – 10:00 CETSelf-rated knowledge and competence regarding the management of chronic kidney disease in primary care10:00 – 10:15Topsever P (Istanbul, Turkey)Shaping the role of primary care in diagnosis of CKD 10:15 – 10:30Itzhak B (Haifa, Israel)Identifying people with CKD in primary care: the role of POCT in KDIGO Guidelines10:30 – 10:45Jacob S (Villingen-Schwenningen, Germany)Diagnosing CKD with UACR in China - Paving the Way for Effective Treatment10:45 – 11:00Yu X (Tongji, China) Discussion11:00 – 11:15Break11:15 – 11:30 CETSGLT-2 inhibitors in CKD: new outcomes to strengthen the bridge to clinical care 11:30 – 11:50Heerspink H (Groningen, Netherlands)Non-steroidal MRAs: recent and future perspectives11:50 – 12:10Rossing P (Copenhagen, Denmark)Discussion12:10 – 12:30Current and future aspects of heart failure management12:30 – 12:45Kosiborod M (Kansas City, USA)CLEAR Outcomes: Reducing cardiovascular mortality and morbidity with bempedoic acid12:45 – 13:00 Ray KK (London, UK) Discussion13:00 – 13:15Break13:15 – 13:45 CETType 2 Diabetes & Cancer 13:45 – 14:00Standl E (Munich, Germany)Obesity & Cancer14:00 – 14:15 Herzig S (Munich, Germany)Discussion14:15 – 14:30Recent advances in incretin therapy14:30 – 14:50Frías JP (Los Angeles, USA)Successful treatment of Type 2 Diabetes and obesity: managing cardiovascular risk and implementing new treatment pathways14:50 – 15:10 Vilsbøll T (Copenhagen, Denmark)Diagnosis, prognosis and future treatments options of fatty liver disease 15:10 – 15:30 Tacke F (Berlin, Germany)How to communicate successfully with people who are obese15:30 – 15:50Snoek F (Amsterdam, Netherlands)Discussion15:50 – 16:15Break16:15 – 16:30 CETIndustry´s perspective - panel discussion 16:30 – 17:30 CETOP 6: Change in Fibrosis-4 Index (FIB4) is Associated With Risk of Liver Events, Cardiovascular Events, and All-Cause Mortality in Patients With Obesity and/or Type 2 Diabetes (T2D)Jara M (Søborg, Denmark)OP 7: Prevalence and Effect of Semaglutide on Non-Alcoholic Steatohepatitis in People With Obesity With and Without Type 2 Diabetes: Analyses From the STEP 1 and 2 Trials Using SomaSignal TestsLong M (Søborg, Denmark)OP 8: Heart Failure in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease With and Without Cardiovascular Autonomic NeuropathyMonashnenko O (Kyiv, Ukraine)OP 9: Glycaemic Control in Users of Automated Insulin Delivery Systems Increased Slightly From 2019 to 2021: Longitudinal Data of the Digitalisation and Technology ReportEhrmann D (Bad Mergentheim, Germany)OP 10: Real-World Evidence Showing Sustained Improvements in Glycemia at 1 Year in People With Type 2 Diabetes Using the OneTouch Reveal® Mobile App With OneTouch® Blood Glucose MetersHolt E (Malvern, USA)Abstract Awards and Closing18:30 – 18:45 CET Schnell O (Munich, Germany) Thank you for your attendance and contribution to the Virtual CVOT Summit 2023.
See you next year for and contribution to the Virtual CVOT Summit 2023.
See you next year for the 10th CVOT Summit on 05 - 06 December , 2024.Thank you for your attendance and contribution to the Virtual CVOT Summit 2023.
See you next year for and contribution to the Virtual CVOT Summit 2023.
See you next year for the 10th CVOT Summit on 05 - 06 December , 2024. We will be right back.We are currently having some technical issues. We will be right back.The page is automatically updated.The next program item is loaded.
Log in with email address and password.
Forgot password?
To log in you need to create a password:
